Fenofibrate - Ethypharm/Lupin

Drug Profile

Fenofibrate - Ethypharm/Lupin

Alternative Names: Antara; Lipilfen; RP-1824

Latest Information Update: 07 Mar 2014

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Ethypharm
  • Developer Daewoong Pharmaceutical; Ethypharm; Lupin
  • Class Antihyperlipidaemics; Benzophenones; Butyric acids; Fibric acid derivatives; Propionates; Small molecules
  • Mechanism of Action Peroxisome proliferator-activated receptor alpha agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Hyperlipidaemia

Most Recent Events

  • 01 Jan 2014 Launched for Hyperlipidaemia in China (PO)
  • 22 Oct 2013 Launched for Hyperlipidaemia (30mg and 90mg doses) in USA (PO)
  • 22 Oct 2013 Registered for Hyperlipidaemia in USA (PO; 30mg and 90mg)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top